08.08.2011 • NewsArch ChemicalsQ2 2011sales and profits

Arch Chemicals Q2 Profit Falls

Biocides company Arch Chemicals, which is in $1.4 billion cash deal to be acquired by Lonza reported that its second-quarter earnings from continuing operations was $37.4 million or $1.47 per share, lower than prior year's $43.5 million or $1.73 per share.

The latest quarter results included a charge of $0.3 million or $0.01 per share, for relocation costs incurred in conjunction with the previously announced research and development consolidation.

Excluding this item, earnings from continuing operations for 2011 were $37.7 million or $1.48 per share.

Analysts polled by Thomson Reuters expected earnings of $1.82 per share for the quarter. Analysts' estimates typically exclude special items.
The company noted that the second-quarter earnings were significantly impacted by lower-than-expected results from the HTH water products business, principally due to timing.

Sales for the second quarter were $443.8 million, compared to $441.4 million for the second quarter of 2010.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.